MAPK3 and neuropathic pain: Although no difference was observed in the total ERK1/2 levels between oxaliplatin and vehicle treatment groups, p-ERK1/2 was found to be up-regulated up to 4.5-fold (447.6 ± 273.6%, P = 0.0029) in DRG of oxaliplatin-induced neuropathic pain rat model (Fig 2).